DRTS — Alpha Tau Medical Ltd.

Is DRTS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Alpha Tau Medical Ltd. (DRTS) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $14.47. The rating moved from Strong Oversold to Overbought on August 4, 2026.

See all overbought Healthcare stocks →

AI analysis

Alpha Tau Medical Ltd. (DRTS) is an early-stage oncology company with a differentiated alpha-particle radiotherapy technology. Near-term value drivers are clinical readouts, regulatory clarity, and partnership/commercialization progress; absent positive, de-risking milestones the company remains reliant on external financing and selective investor appetite. The outlook includes meaningful upside if trials and commercialization proceed smoothly but material downside linked to trial, regulatory, reimbursement, or execution failures.

Key factors

  • Proprietary alpha-emitting radiotherapy platform targeting solid tumors with a differentiated mechanism of action versus external-beam and beta-emitting radiotherapies
  • Early-stage clinical data and investigator-led studies have shown signals of activity in selected tumor types, providing identifiable clinical catalysts (trial readouts, expanded cohorts)
  • Large addressable market in interventional oncology and potential complementary demand from improved diagnostic/screening workflows
  • Commercialization and scaling depend on partnerships, reimbursement acceptance, and establishment of physician adoption pathways
  • Current market environment is neutral-to-selective for growth healthcare names, which can constrain near-term rerating absent visible commercial traction
  • Limited public filings and social/research coverage create higher idiosyncratic uncertainty and reliance on sporadic corporate disclosures

Risks

  • Clinical trial outcomes may be negative or inconclusive, materially reducing commercial prospects
  • Regulatory approval pathway for novel alpha therapies could be prolonged, ambiguous, or require additional expensive studies
  • Reimbursement and payer acceptance for a novel radiotherapeutic approach are uncertain and could limit commercial uptake
  • Capital raised via equity or other financing could cause dilution if revenue/partner milestones are delayed
  • Competition from established radiotherapy modalities, targeted agents, immunotherapies, and other radiopharmaceutical approaches
  • Manufacturing, supply-chain scale-up, and treatment delivery logistics (radiation handling, training) pose operational execution risk
  • Low trading liquidity and limited analyst coverage may amplify price volatility on newsflow

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for DRTS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.